Arvinas (ARVN) Stock
Research-focused biotech developing new cancer treatment options. Here's the price, business snapshot, and what's worth knowing about Arvinas in October 2026.
Arvinas Inc (ARVN) is a clinical-stage biotechnology company developing targeted protein degraders — molecules designed to remove disease-causing proteins rather than merely inhibit them. Its pipeline centres on programmes for hormone-driven cancers (oestrogen and androgen receptor degraders) and earlier-stage assets exploring other disease areas. With a market capitalisation of about $709.21m, Arvinas is a small-cap, research-led firm: its value is closely tied to clinical trial results, regulatory decisions and potential licensing or partnership deals. The company has secured industry collaborations that can provide funding and development expertise, but commercial success is not guaranteed. Investing in Arvinas offers exposure to a differentiated scientific platform with upside if key trials succeed, while also carrying typical biotech risks such as trial setbacks, lengthy development timelines and potential equity dilution from fundraising. This summary is educational general information only and not personalised investment advice; investors should assess suitability and risk tolerance before acting.
Arvinas (ARVN) Stock Forecast
Analyst price target, next 12 months
$43.29
+493.0% vs today's $7.30
Price range over the last 12 months
Close to its 12-month low
Analysts covering Arvinas have a consensus 12-month target of $43.29, above the current price of $7.30.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Arvinas' stock with a target price of $43.29, indicating significant growth potential.
Financial Health
Arvinas Inc is performing well with strong revenue, cash flow, and gross margin metrics.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can materially move the share price; outcomes are binary and timings uncertain, so expect volatility.
Platform Potential
Targeted protein degradation could broaden treatable diseases and create new medicines, though the science is still early and success is not assured.
Partner Collaborations
Industry partnerships can provide funding and development expertise, helping de‑risk programmes, but commercialisation and market uptake remain to be proven.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
